Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Clinical Trial on Application of Injectable Recombinant Human Luteinizing Hormone (Luveris) in the Treatment of Chinese Female Patients With Hypogonadotropic Hypogonadism: A Multi-center, Open, Prospective Drug Clinical Trial for Registration

Trial Profile

Clinical Trial on Application of Injectable Recombinant Human Luteinizing Hormone (Luveris) in the Treatment of Chinese Female Patients With Hypogonadotropic Hypogonadism: A Multi-center, Open, Prospective Drug Clinical Trial for Registration

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 08 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lutropin alfa (Primary) ; Chorionic gonadotropin; Follitropin alfa
  • Indications Female infertility
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Merck KGaA

Most Recent Events

  • 22 May 2012 Official Title amended as reported by ClinicalTrials.gov.
  • 22 May 2012 Actual end date changed from Feb 2005 to Dec 2005 as reported by ClinicalTrials.gov.
  • 22 May 2012 Actual initiation date changed from Jun 2004 to Feb 2004 as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top